Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia

[1]  J. Lieberman,et al.  Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  J. Lieberman,et al.  A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia , 2010, Neuropsychopharmacology.

[3]  B. Hudson,et al.  Ligand- and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor , 2010, Molecular Pharmacology.

[4]  P. Donahoe,et al.  HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis , 2009, Proceedings of the National Academy of Sciences.

[5]  J. Satsangi,et al.  The genetics of Crohn's disease. , 2009, Annual review of genomics and human genetics.

[6]  J. Lieberman,et al.  Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia , 2009, European Neuropsychopharmacology.

[7]  J. Fernández-Ruiz.  The endocannabinoid system as a target for the treatment of motor dysfunction , 2009, British journal of pharmacology.

[8]  J. Lieberman,et al.  Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia , 2008, Schizophrenia Research.

[9]  Anatol C. Kreitzer,et al.  Striatal Plasticity and Basal Ganglia Circuit Function , 2008, Neuron.

[10]  Jeffrey A. Lieberman,et al.  Extrapyramidal side-effects of antipsychotics in a randomised trial , 2008, British Journal of Psychiatry.

[11]  B. Thelma,et al.  Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. , 2008, Pharmacogenomics.

[12]  István Katona,et al.  Endocannabinoid signaling as a synaptic circuit breaker in neurological disease , 2008, Nature Medicine.

[13]  P. Greengard,et al.  Dichotomous Dopaminergic Control of Striatal Synaptic Plasticity , 2008, Science.

[14]  Alastair Forbes,et al.  Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease , 2008, Nature Genetics.

[15]  R. Moratalla,et al.  Expression and Function of CB1 Receptor in the Rat Striatum: Localization and Effects on D1 and D2 Dopamine Receptor-Mediated Motor Behaviors , 2008, Neuropsychopharmacology.

[16]  T. Karlsen,et al.  Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis , 2008, Nature Genetics.

[17]  C. Correll,et al.  Tardive dyskinesia and new antipsychotics , 2008, Current opinion in psychiatry.

[18]  J. Lieberman,et al.  Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. , 2007, The international journal of neuropsychopharmacology.

[19]  D. Surmeier,et al.  D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons , 2007, Trends in Neurosciences.

[20]  Robert C. Malenka,et al.  Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.

[21]  T. Freund,et al.  Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia , 2006, Neuroscience.

[22]  R. Baldessarini,et al.  Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? , 2006, Movement disorders : official journal of the Movement Disorder Society.

[23]  Wj Gauderman,et al.  QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies , 2006 .

[24]  J. Li,et al.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.

[25]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[26]  G. Uhl,et al.  Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse , 2004, Molecular Psychiatry.

[27]  T. Shinkai,et al.  Clinical implications of pharmacogenomics for tardive dyskinesia , 2004, The Pharmacogenomics Journal.

[28]  D. Nyholt.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.

[29]  J. Lieberman,et al.  Clozapine pharmacology and tardive dyskinesia , 2004, Psychopharmacology.

[30]  F. Dudbridge.  Pedigree disequilibrium tests for multilocus haplotypes , 2003, Genetic epidemiology.

[31]  S. Leucht,et al.  New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.

[32]  M. van der Stelt,et al.  The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. , 2003, European journal of pharmacology.

[33]  J. Gerlach.  Improving Outcome in Schizophrenia: The Potential Importance of EPS and Neuroleptic Dysphoria , 2002, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[34]  M. Rietschel,et al.  Familial occurrence of tardive dyskinesia. , 1998, Acta psychiatrica Scandinavica.

[35]  M. Maršálek.  Tardive Drug-Induced Extrapyramidal Syndromes , 2000, Pharmacopsychiatry.

[36]  H. Arnold,et al.  NKX2.3 is required for MAdCAM‐1 expression and homing of lymphocytes in spleen and mucosa‐associated lymphoid tissue , 2000, The EMBO journal.

[37]  Fabio Macciardi,et al.  Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia , 1999, Neuropsychopharmacology.

[38]  M. Herkenham,et al.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  L. Parsons,et al.  Dopamine activation of endogenous cannabinoid signaling in dorsal striatum , 1999, Nature Neuroscience.

[40]  F. Fonseca,et al.  Role of the Endogenous Cannabinoid System in the Regulation of Motor Activity , 1998, Neurobiology of Disease.

[41]  M. Rosenfeld,et al.  Brn-5 is a divergent POU domain factor highly expressed in layer IV of the neocortex. , 1993, The Journal of biological chemistry.

[42]  J. Nurnberger,et al.  A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. , 1991, Nucleic acids research.

[43]  Daniel E. Casey,et al.  Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia , 1991, Schizophrenia Research.

[44]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[45]  J. Lieberman,et al.  Prevalence of tardive dyskinesia in elderly samples. , 1984, Psychopharmacology bulletin.

[46]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.